BUSINESS

Xofluza Sees Sharp Sales Decline, but Inavir Logs Growth: 2019-2020 Flu Drug Market

May 13, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Shionogi’s anti-flu drug Xofluza (baloxavir marboxil) suffered a 98.4% sales decline in FY2019. The company attributes this drop to factors including a short flu season and hospital avoidance amid the coronavirus outbreak. In contrast, sales of Daiichi Sankyo’s Inavir (laninamivir)…

To read the full story

Shionogi Suffers Lower Earnings as Xofluza Sales Dive 98.4% in FY2019
May 12, 2020
Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
October 28, 2019

BUSINESS

Eisai to Raise 50 Billion Yen via Bond Issue for R&D, Licensing
June 5, 2026
Japan Market for Fertility, Contraception, Female Disorders Put at 228.5 Billion Yen by FY2035
June 5, 2026
Toho, DHL Partner on Healthcare Logistics Platform
June 5, 2026
Keytruda Maintains Lead as Japan’s Top-Selling Drug for 32nd Month: Encise
June 5, 2026
Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…